For the 18 million people living with rheumatoid arthritis, disease management currently means a lifetime of injections-a ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A new therapeutic approach for rheumatoid arthritis (RA) could help ...

Beijing: A research team from north China's Tianjin University has developed a new type of injectable hydrogel that can regulate immune cell metabolism, helping to reduce inflammation and slow down ...

Scientists in China have developed an injectable hydrogel aimed at treating early-stage osteoarthritis. The biomaterial is said to relieve arthritis-related discomfort and slow the condition's ...

Many people living with rheumatoid arthritis (RA) rely on long-term medications to manage joint pain, stiffness, and inflammation. A number of these treatments are given as subcutaneous injections, ...

Knee osteoarthritis is one of the most common causes of pain and disability around the world. The condition develops when the ...

This joint-specific response pattern was consistent across all advanced treatment modalities, including abatacept, interleukin-6 receptor inhibitors, Janus kinase inhibitors, rituximab and TNFi.

Early treatment with DMARDs improved short-term disease activity in undifferentiated arthritis, though long-term outcomes remained similar.